Nkarta Posts Narrower Loss in Q2
Nkarta ( NASDAQ:NKTX ) , a clinical-stage biotechnology company specializing in allogeneic NK cell therapies for autoimmune diseases, reported its second-quarter earnings on August 12, 2025, covering results for the period ended June 30, 2025.
Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series - Nkarta ( NASDAQ:NKTX )
SOUTH SAN FRANCISCO, Calif., July 23, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. NKTX, a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the H.C. Wainwright "HCW@Home" Series.
Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series
SOUTH SAN FRANCISCO, Calif., July 23, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the H.C. Wainwright "HCW@Home" Series.
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
SOUTH SAN FRANCISCO, Calif., June 09, 2025 ( GLOBE NEWSWIRE ) -- Lyell Immunopharma, Inc. ( Nasdaq: LYEL ) , a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J.
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - Lyell Immunopharma ( NASDAQ:LYEL )
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D.
Nkarta ( NKTX ) Moves to Buy: Rationale Behind the Upgrade
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Nkarta ( NASDAQ:NKTX )
Q1 net loss of $0.43 per share beat the consensus estimate of a $0.44 loss. Nkarta holds $351.9 million in cash and expects it to last through 2029. Don't miss this list of 3 high-yield stocks-including one delivering over 10%-built for income in today's chaotic market. Nkarta Inc.
This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Alcoa ( NYSE:AA ) , Americold Realty Trust ( NYSE:COLD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Samik Chatterjee downgraded the rating for Luminar Technologies, Inc.
Nkarta ( NKTX ) Upgraded to Buy: Here's Why
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D. - Senti Biosciences ( NASDAQ:SNTI )
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth ...
Nkarta to Participate in an April Investor Conference - Nkarta ( NASDAQ:NKTX )
SOUTH SAN FRANCISCO, Calif., April 01, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. NKTX, a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference:
Nkarta to Participate in an April Investor Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference: ...
Nkarta to Participate in an April Investor Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference:
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Nkarta ( NASDAQ:NKTX )
Nkarta posted a Q4 loss of $0.35 per share, beating estimates of a $0.41 loss, and announced a 34% workforce reduction. Nkarta holds $380.5M in cash and investments as of Dec. 31, 2024, expected to fund operations into 2029. Feel unsure about the market's next move?
Nkarta ( NKTX ) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Nkarta ( NKTX ) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nkarta (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Nkarta to Participate in March Investor Conferences - Nkarta ( NASDAQ:NKTX )
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. NKTX, a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conferences:
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conferences: ...
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 - Nkarta ( NASDAQ:NKTX )
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial ( IST ) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for ...
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts ...
Nkarta to Participate in an Upcoming Investor Conference - Nkarta ( NASDAQ:NKTX )
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. NKTX, a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference:
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference: ...
Nkarta to Participate in an Upcoming Investor Conference - Nkarta ( NASDAQ:NKTX )
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. NKTX, a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference: Stifel 2024 Healthcare Conference November ...
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference: ...
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Moderna ( NASDAQ:MRNA )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Why Nkarta Stock Is Soaring Today
One analyst is now more bullish about this clinical-stage biotech stock.
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday - UBS Gr ( NYSE:UBS )
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Wednesday. Shares of UBS Group AG UBS rose during Wednesday's session following strong second-quarter earnings. UBS Group reported second-quarter FY24 sales of $11.9 billion, up 25% Y/Y, beating the consensus of $11.3 ...
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Alternus Clean Energy ( NASDAQ:ALCE ) , Bionomics ( NASDAQ:BNOX )
Shares of Serve Robotics Inc. SERV rose sharply in today's pre-market trading as the company reported better-than-expected second-quarter sales results. Serve Robotics reported quarterly losses of 27 cents per share which missed the analyst consensus estimate for a loss of 25 cents per share.
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
VANCOUVER, British Columbia, July 25, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the ...
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, July 25, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
SOUTH SAN FRANCISCO, Calif., July 24, 2024 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced that researchers at Columbia University Irving Medical Center ( CUIMC ) have initiated an ...
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
SOUTH SAN FRANCISCO, Calif., July 16, 2024 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, ...
Nkarta ( NKTX ) Upgraded to Buy: Here's What You Should Know
Nkarta (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis ...
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing - Century Therapeutics ( NASDAQ:IPSC )
Thursday, Century Therapeutics IPSC unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.
Top 1% Biotech Soars To Year-High After Epilepsy Drug Scores Big
Praxis Precision Medicine ( PRAX ) said Tuesday every patient in a midstage study responded to its experimental epilepsy treatment. The top 1% biotech stock rocketed to a year high. The company tested two doses of its drug in patients with photoparoxysmal response, a seizure disorder tied to ...
Viking Surges After Weight-Loss Pill Beats Forecasts In Just 28 Days
Viking Stock Surges After Weight-Loss Drug Tops Expectations Investor's Business Daily ...
Nasdaq Turns Higher; Akanda Shares Plunge - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also fell, dropping, 0.12% to 5,227.95. In trading on Monday, industrials shares fell by 0.5%.
Crude Oil Moves Higher; US New Home Sales Fall In February - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S&P 500 also fell, dropping, 0.16% to 5,226.01. In trading on Monday, communication services ...
Masimo Breaks Out On Potential Separation; But Will Profits Hold Up?
Masimo Stock Breaks Out On Potential Consumer-Business Separation Investor's Business Daily ...
Why This Biotech Just Boomeranged From Its Friday Dive
Nkarta Stock Boomerangs Following Massive Flop On Friday Investor's Business Daily ...
Nkarta Announces Pricing of $240 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., March 25, 2024 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of ...
Why This Top 1% Biotech Stock Just Plummeted 31%
Nkarta Stock Plummets After Biotech Deprioritizes Cancer Drug Investor's Business Daily ...
Why Is Nkarta Stock Trading Lower On Friday? - Nkarta ( NASDAQ:NKTX )
Thursday, in its fourth quarter 2023 earnings release, Nkarta Inc NKTX said it closed patient enrollment in its clinical trial of NKX101 and deprioritized the program as part of a pipeline realignment that directs primary resources to its lead pipeline program, NKX019, for autoimmune disease.
Why This Top 1% Biotech Stock Just Plummeted 22%
Nkarta Stock Plummets After Biotech Scraps Cancer Drug For Lupus Treatment Investor's Business Daily ...
FedEx To Rally Over 32%? Here Are 10 Top Analyst Forecasts For Friday - FedEx ( NYSE:FDX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush boosted the price target for Chipotle Mexican Grill, Inc. CMG from $2,400 to $2,850.
